Buruli ulcer

British Medical Journal

Volumn 330, Issue 7505, 2005, Pages 1402-1403

  Wansbrough Jones, Mark ^a   Phillips, Richard ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; NITROGEN OXIDE; PHENYTOIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL GENOME; BURULI ULCER; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; EDITORIAL; HUMAN; INSECT BITE; MYCOBACTERIUM ULCERANS; PRIORITY JOURNAL;

EID: 21044432338     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7505.1402     Document Type: Editorial

References (12)

1. Asiedu K, Scherpbier R, Raviglione M. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: World Health Organization, 2000. www.who.int/gtb-buruli/publications/PDF/Buruli_ulcer_monograph.PDF (accessed 21 Apr 2005).
2. Marsollier L, Aubry J, Saint-Andre JP, Robert R, Legras P, Manceau AL, et al. [Ecology and transmission of Mycobacterium ulcerans]. Pathol Biol (Paris) 2003;51:490-5.
3. Stinear TP. The complete genome sequence of Mycobacterium ulcerans strain Agy99. Report of the 8th annual WHO advisory group meeting on Buruli ulcer. 2005. (In press.)
4. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999;283:854-7.
5. George KM, Pascopella L, Welty DM, Small PL. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 2000;68:877-83.
6. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 2004;101:1345-9.
7. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 2002;46:3193-6.
8. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsefield C, Phillips R, et al. Bactericidal activity of rifampicin and streptomycin treatment for early human M. ulcerans lesions. Report of the 7th Annual WHO Advisory Group Meeting on Buruli ulcer. 2004. p110. www.who.int/gtb-buruli/publications/PDF/WHO-CDS- CPE-GBUI-2004.9.pdf (accessed 21 Apr 2005).
9. Chauty A. Drug treatment in Benin. Report of the 8th Annual WHO Advisory Group Meeting on Buruli ulcer. 2005. (In press.)
10. Revill WD, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 1973;2:873-7.
11. Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M. Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob Agents Chemother 2004;48:2866-70.
12. Phillips R, Kuijper S, Benjamin N, Wansbrough-Jones M, Wilks M, Kolk AH. In vitro killing of Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents Chemother 2004;48:3130-2.